APOA1 and coronary atherosclerosis: Using recombinant apoA1 particles, Nissen and colleagues showed regression of coronary atherosclerosis in patients given 5 weekly intravenous injections (Nissen et al., 2003; Kingwell et al., 2014), and it is tempting to speculate that the efficacy was due, at least in part, by the mechanisms illustrated by our studies.